Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Declines By 15.7%

Biomerica, Inc. (NASDAQ:BMRA) saw a significant drop in short interest in February. As of February 27th, there was short interest totaling 60,973 shares, a drop of 15.7% from the February 12th total of 72,362 shares. Approximately 2.5% of the company’s shares are short sold. Based on an average trading volume of 15,903 shares, the short-interest ratio is currently 3.8 days. Based on an average trading volume of 15,903 shares, the short-interest ratio is currently 3.8 days. Approximately 2.5% of the company’s shares are short sold.

Biomerica Price Performance

Shares of NASDAQ BMRA opened at $2.00 on Tuesday. Biomerica has a 1-year low of $1.87 and a 1-year high of $5.92. The business’s 50 day moving average is $2.32 and its two-hundred day moving average is $2.55. The stock has a market capitalization of $6.04 million, a P/E ratio of -2.15 and a beta of 0.21.

Biomerica (NASDAQ:BMRA) last posted its quarterly earnings data on Wednesday, January 14th. The company reported ($0.45) earnings per share (EPS) for the quarter. The company had revenue of $1.21 million during the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 83.73%.

Institutional Trading of Biomerica

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC boosted its position in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the quarter. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 as of its most recent filing with the Securities & Exchange Commission. 22.28% of the stock is owned by hedge funds and other institutional investors.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.